(thirdQuint)Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer.

 The study will be conducted in two phases: dose escalation and expansion.

 Up to three dose levels of SBP-101 will be assessed in up to 18 subjects during dose escalation.

 The expansion phase of the study will consist of 10 additional subjects who will receive the recommended dose of SBP-101 combined with nab-paclitaxel and gemcitabine.

.

 Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer@highlight

This is an open-label phase 1A/1B study to assess the safety, tolerability and pharmacokinetics of SBP-101 when combined with nab-paclitaxel and gemcitabine in subjects with previously untreated metastatic pancreatic ductal adenocarcinoma and to identify a recommended phase 2 dose.

 The study will also assess preliminary efficacy of the 3-drug treatment combination.

